Loading…

ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2019-06, Vol.37 (S2), p.71-72
Main Authors:	Cummin, T.E., Caddy, J., Mercer, K., Maishman, T., Schuh, A., Lopez Pascua, L., Collins, G., McMillan, A., Ardeshna, K., Galanopoulous, A., Burton, C., Barrans, S., Griffiths, G., Johnson, P., Davies, A.J.
Format:	Article
Language:	English
Subjects:	B-cell lymphoma Cyclophosphamide Doxorubicin Immunotherapy Lymphocytes B Lymphoma Monoclonal antibodies Prednisolone Rituximab Targeted cancer therapy Vincristine
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!